Argatroban is filed as Direct thrombin inhibitor. The sections below restate public label fields stored for this profile.
Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT). ( 1.1 ) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI). ( 1.2 )
Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor anti-thrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation. Argatroban inhibits thrombin with an inhibition constant (Ki) of 0.04 μM. At therapeutic concentrations, argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin.
5 WARNINGS AND PRECAUTIONS • Hemorrhage can occur. Unexplained fall in hematocrit or blood pressure may indicate hemorrhage. ( 5.1 ) • Hepatic impairment: Adjust starting dose and titrate carefully in patients with HIT who have moderate or severe hepatic impairment. Avoid use in PCI in patients with clinically significant hepatic impairment. ( 5.2 ) 5.1 Risk of Hemorrhage Hemorrhage can occur at any site in the body in patients receiving argatroban. Unexplained fall in hematocrit or blood pressure may indicate hemorrhage. Intracranial and retroperitoneal hemorrhage [see Adverse Reactions (6.1) ] has been reported. The risk of hemorrhage with argatroban may be increased in severe hypertension, immediately following lumbar puncture, spinal anesthesia, major surgery (especially involving the brain, spinal cord, or eye), hematologic conditions associated with increased bleeding tendencies such as congenital or acquired bleeding disorders, and gastrointestinal lesions such as ulcerations. Concomitant use of argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding. 5.2 Use in Hepatic Impairment When administering argatroban to patients with hepatic impairment, start with a lower dose and carefully titrate until the desired level of anticoagulation is achieved. Achievement of steady state aPTT levels may take longer and require more argatroban dose adjustments in patients with hepatic impairment compared to patients with normal hepatic function [ see Use in Specific Populations (8.6) ] . Also, upon cessation of argatroban infusion in the hepatically impaired patient, full reversal of anticoagulant effects may require longer than 4 hours due to decreased clearance and increased elimination half-life of argatroban [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] . Avoid the use of high doses of argatroban in patients undergoing PCI who have clinically significant hepatic disease or AST/ALT levels greater than or equal to 3 times the upper limit of normal. 5.3 Laboratory Tests Anticoagulation effects associated with argatroban infusion at doses up to 40 mcg/kg/min correlate with increases of the aPTT. Although other global clot-based tests including prothrombin time (PT), the International Normalized Ratio (INR), and thrombin time (TT) are affected by argatroban, the therapeutic ranges for these tests have not been identified for argatroban therapy. In clinical trials in PCI, the ACT was used for monitoring argatroban anticoagulant activity during the procedure. The concomitant use of argatroban and warfarin results in prolongation of the PT and INR beyond that produced by warfarin alone [ see Dosage and Administration (2.5) and Clinical Pharmacology (12.2) ] .
Argatroban is contraindicated in: Patients with major bleeding, [see Warnings and Precautions (5.1) ] Patients with a history of hypersensitivity to argatroban. Airway, skin, and generalized hypersensitivity reactions have been reported [see Adverse Reactions (6.1) ]
The most common (>5%); Ted by decreasing frequency of occurrence (≥2%); Bserved non-hemorrhagic adverse reactions (>2%); Patients (4.3%)
The following adverse reaction is also discussed in other sections of the labeling: Risk of Hemorrhage [ see Warnings and Precautions (5.1) ].
Argatroban Injection, USP 50 mg/50 mL (1 mg/mL) is ready for intravenous infusion. Dilution is not required. ( 2.1 ) Heparin-Induced Thrombocytopenia The dose for heparin-induced thrombocytopenia without hepatic impairment is 2 mcg/kg/min administered as a continuous infusion. ( 2.2 ) Percutaneous Coronary Intervention The dose for patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention is started at 25 mcg/kg/min and a bolus of 350 mcg/kg administered via a large bore intravenous line over 3 to 5 minutes. ( 2.3 )
Heparin: Allow sufficient time for heparin’s effect on activated partial thromboplastin time (aPTT) to decrease before initiating Argatroban Injection therapy. ( 7.1 ) Warfarin: Concomitant use results in increased prolongation of PT and INR. ( 7.2 ) Thrombolytic agents or glycoprotein IIb/IIIa antagonists: Safety and effectiveness of concomitant use with argatroban have not been established. ( 7.4 , 7.5 )
According to its FDA label, Argatroban is approved for: Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT). ( 1.1 ) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI… For medical advice, please talk to your prescriber or pharmacist.
Argatroban belongs to the Direct thrombin inhibitor class of medications.
The FDA label lists Argatroban as: Hemorrhage can occur. Unexplained fall in hematocrit or blood pressure may indicate hemorrhage ( 5.1 ) Hepatic impairment: Adjust starting dose and titrate carefully in patients with HIT who have moderate or severe hepatic impairment. Avoid use in PCI in patients with clinically significant hepatic impairment. ( 5.2 ); intravenous route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Argatroban is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Argatroban does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Argatroban in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Argatroban as 2012-01-05.
The FDA label lists Hikma Pharmaceuticals USA Inc. as a labeler/manufacturer of Argatroban. Multiple firms may market generics of the same molecule.
The FDA label states: "Argatroban Injection, USP is a clear colorless to pale yellow color solution, free from visible particulates. Argatroban Injection, USP is available in packages as follows: NDC Strength Packaged 65145-126-01 50 mg/50 mL…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…